Hasan Cagri Yildirim
Overview
Explore the profile of Hasan Cagri Yildirim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yay F, Yildirim H, Kus F, Yalcin S
Biomarkers
. 2025 Jan;
:1-20.
PMID: 39847517
Background: Dynamins are defined as a group of molecules with GTPase activity. Among them, DNM3 has gained recognition in oncology for its tumor suppressor role. Based on this, the aim...
2.
Yildirim C, Yay F, Imre A, Soysal O, Yildirim H
Genes (Basel)
. 2025 Jan;
15(12.
PMID: 39766770
Hepatitis C infections are the main causes of fatal clinical conditions such as cirrhosis and HCC development, and biomarkers are needed to predict the development of these complications. Therefore, it...
3.
Majidova N, Aghamaliyeva S, Guliyev M, Dinc G, Akyildiz A, Ozcan E, et al.
J Chemother
. 2024 Nov;
:1-6.
PMID: 39588941
Managing locally advanced, or metastatic radioactive iodine-refractory differentiated thyroid cancers (RAIR-DTC) poses substantial challenges, with few available treatment options. The aim of this study was to evaluate clinical outcomes of...
4.
Kus F, Guven D, Yildirim H, Akagunduz B, Karakaya S, Sutcuoglu O, et al.
Integr Cancer Ther
. 2024 Oct;
23:15347354241280273.
PMID: 39367737
Aims: This study aimed to assess the habits and knowledge of cancer patients regarding the use of herbal medicines and dietary supplements in cancer patients receiving immune checkpoint inhibitors (ICI)....
5.
Yilmaz F, Yasar S, Tatar O, Yildirim H, Guven D, Akyildiz A, et al.
BMC Cancer
. 2024 Oct;
24(1):1218.
PMID: 39354432
Background: Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC. In the second line, weekly...
6.
Esin E, Yildirim H, Oksuzoglu B, Markoc F, Guntekin S, Bilgetekin I, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274541
Therapeutic decisions in early breast cancer are based on clinico-pathological features which are subject to intra- and inter-observer variability. This single-center decision impact study aimed to evaluate the effects of...
7.
Yildirim H, Bayram E, Chalabiyev E, Majidova N, Avci T, Guzel H, et al.
J Chemother
. 2024 Sep;
:1-12.
PMID: 39257075
Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial...
8.
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
Kus F, Guven D, Yildirim H, Chalabiyev E, Akyildiz A, Tatar O, et al.
Biomark Med
. 2024 Aug;
18(10-12):511.
PMID: 39136458
No abstract available.
9.
Yildirim H, Buyukkor M, Kavgaci G, Celik B, Yucel K, Dursun B, et al.
Medicine (Baltimore)
. 2024 Jul;
103(30):e38828.
PMID: 39058877
The fact that the human epidermal growth factor receptor 2 (HER2)-low group, historically classified as HER2 negative in breast cancer histology, benefited from HER2-targeted treatments similarly to the HER2-positive group...
10.
Akyildiz A, Gultekin M, Yigit E, Demir E, Ismayilov R, Ahmed M, et al.
Int J Gynecol Cancer
. 2024 Jul;
34(9):1359-1365.
PMID: 38950923
Objective: To investigate the impact of cumulative cisplatin dose on clinical outcomes in locally advanced cervical cancer patients undergoing definitive chemoradiotherapy. Methods: A retrospective analysis was conducted on 654 patients...